Skip to main content
Premium Trial:

Request an Annual Quote

Nuclea Biotech, Berkshire Medical Center Collaborate on Prostate, Breast Cancer Biomarker Identification

NEW YORK (GenomeWeb News) – Nuclea Biotechnologies today announced a research and collaboration agreement with Berkshire Medical Center aimed at prostate cancer and breast cancer biomarker identification.

As part of the deal, Berkshire — the primary affiliate of Berkshire Health Systems — will provide Nuclea with samples of serum and tumor tissue for the identification of biomarkers for cancer diagnostics, with patient consent. Pittsfield, Mass.-based Nuclea develops genetic, protein, and antibody biomarkers and diagnostic assays to help determine which therapeutics may be most appropriate for individual patients.

Last month, it said it raised $4.2 million of a targeted $5 million in a Series D round.

Financial and other terms of the today's deal were not disclosed.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.